The European Union Cloud Services Scheme (“EUCS”) is a certification framework for cloud services introduced under the EU Cybersecurity Act. Currently still under consultation, the EUCS, once finalised, will be implemented by...more
Artificial intelligence (AI) and machine learning (ML) technology have started to transform financial services and bring about new business opportunities, but with risks. AI governance should be adopted by financial...more
As in other fields of digital transformation, the EU Commission wants to set a standard with its draft regulations for both cryptoassets, and artificial intelligence. But is it ready for the challenge? Both technologies will...more
9/7/2021
/ Artificial Intelligence ,
Blockchain ,
Cryptoassets ,
Cryptocurrency ,
Cybersecurity ,
Digital Services ,
Distributed Ledger Technology (DLT) ,
European Commission ,
Financial Regulatory Agencies ,
Financial Services Industry ,
FinTech ,
Non-Fungible Tokens (NFTs) ,
Popular
What is Living Mobility? It is easier to say what it is not. The automotive industry is no longer focused on the traditional vehicle. Not only are the vehicles changing but we are now focused on mobility: different modes of...more
6/23/2021
/ Artificial Intelligence ,
Automation Systems ,
Automotive Industry ,
Blockchain ,
Climate Change ,
Connected Cars ,
Cybersecurity ,
Data Privacy ,
Drones ,
Electric Vehicles ,
Innovative Technology ,
Manufacturers ,
Motor Vehicles ,
Public Private Partnerships (P3s) ,
Supply Chain ,
Unmanned Aircraft Systems
We are pleased to provide you with the third annual installment of our Life Sciences and Health Care Horizons guide. For each of these guides, we have asked our industry thought leaders throughout the world to write about...more
2/26/2020
/ 3D Printing ,
AIDS ,
Analytics ,
Artificial Intelligence ,
Biosimilars ,
Biotechnology ,
Blockchain ,
California Consumer Privacy Act (CCPA) ,
Cyber Threats ,
Cybersecurity ,
Data Breach ,
Department of Defense (DOD) ,
Digital Health ,
Drug Distribution ,
Drug Pricing ,
EU ,
Federal Funding ,
Food and Drug Administration (FDA) ,
General Data Protection Regulation (GDPR) ,
Health Technology ,
HIV ,
Incident Response Plans ,
Intellectual Property Protection ,
Life Sciences ,
Medical Device Data System ,
Medical Devices ,
Medical Software ,
Over The Counter Drugs (OTC) ,
Pharmaceutical Industry ,
PHI ,
Prescription Drugs ,
Procurement Guidelines ,
Regulatory Standards ,
Research and Development ,
Right to Try ,
Robotics ,
Supply Chain ,
Telehealth
“Getting to Data Nirvana” is our four-step approach to help you integrate your legal, regulatory and compliance work streams into your organisation’s overall data strategy.
...more
7/31/2018
/ Compliance ,
Corporate Governance ,
Cybersecurity ,
Data Privacy ,
Data Protection ,
Data Security ,
EU Data Protection Laws ,
General Data Protection Regulation (GDPR) ,
Personal Data ,
Personally Identifiable Information ,
Policies and Procedures ,
Regulatory Requirements ,
Risk Management
Our Insurance Horizons 2018 brochure considers the impact of technology, interest rates, protectionism, excess capacity in the reinsurance market and cyber risk. We also look in detail at M&A in the industry, sanctions and...more
5/16/2018
/ Acquisitions ,
Consumer Insurance Products ,
Covered Agreement ,
Cybersecurity ,
Driverless Cars ,
IAIS ,
IFRS ,
Interest Rates ,
Life Insurance ,
Mergers ,
Regulatory Oversight ,
Reinsurance ,
Risk-Based Approaches ,
Senior Managers Insurers Regime (SMIR) ,
Technology ,
UK Brexit
Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies were still in small-scale clinical...more
4/4/2018
/ 3D Printing ,
Acquisitions ,
Artificial Intelligence ,
Biologics ,
Biosimilars ,
Biotechnology ,
Blockchain ,
Cyber Attacks ,
Cybersecurity ,
Data Breach ,
Digital Health ,
Distributed Ledger Technology (DLT) ,
Drug Pricing ,
Emerging Markets ,
EU ,
General Data Protection Regulation (GDPR) ,
Generic Drugs ,
Innovation ,
Life Sciences ,
Medical Reimbursement ,
Mergers ,
Over The Counter Derivatives (OTC) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Private Equity ,
Regulatory Oversight ,
Supply Chain ,
Transfer Pricing ,
UK Brexit ,
Yates Memorandum